Cargando…

Clinical outcome of FLAG-IDA chemotherapy sequential with Flu–Bu3 conditioning regimen in patients with refractory AML: a parallel study from Shanghai Institute of Hematology and Institut Paoli-Calmettes

The purpose of the study was to evaluate the feasibility of conditioning regimen with sequential chemotherapy (FLAG-IDA), followed by Fludarabine (5 days) + Busulfan (3 days) by parallel analysis of patients with refractory acute myeloid leukemia (AML) from two transplantation centers in China and F...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Ling, Devillier, Raynier, Wan, Ming, Decroocq, Justine, Tian, Liang, Fürst, Sabine, Wang, Li-Ning, Vey, Norbert, Fan, Xing, Blaise, Didier, Hu, Jiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6462832/
https://www.ncbi.nlm.nih.gov/pubmed/30082853
http://dx.doi.org/10.1038/s41409-018-0283-5
_version_ 1783410648197103616
author Wang, Ling
Devillier, Raynier
Wan, Ming
Decroocq, Justine
Tian, Liang
Fürst, Sabine
Wang, Li-Ning
Vey, Norbert
Fan, Xing
Blaise, Didier
Hu, Jiong
author_facet Wang, Ling
Devillier, Raynier
Wan, Ming
Decroocq, Justine
Tian, Liang
Fürst, Sabine
Wang, Li-Ning
Vey, Norbert
Fan, Xing
Blaise, Didier
Hu, Jiong
author_sort Wang, Ling
collection PubMed
description The purpose of the study was to evaluate the feasibility of conditioning regimen with sequential chemotherapy (FLAG-IDA), followed by Fludarabine (5 days) + Busulfan (3 days) by parallel analysis of patients with refractory acute myeloid leukemia (AML) from two transplantation centers in China and France. A total of 47 refractory AML with median bone marrow blast of 35% (1–90%) and median age at 42 years (16–62) were enrolled. Thirteen patients received peripheral stem cell transplantation (HSCT) from HLA-matched sibling donor, while 18 and 16 from unrelated or haplo-identical donors, respectively. With a median follow-up of 24.3 months (1–70), 13 patients relapsed at a median time of 5.1 months (2.2–18.0) and 24 patients died due to relapse (n = 12) or non-relapsed mortality (NRM, n = 12). The estimated 3-year RR and NRM were 33.5 ± 5.7% and 25.7 ± 4.2%, respectively. The estimated 3-year overall survival (OS) and event-free survival (EFS) were 43.8 ± 7.8% and 42.3 ± 7.8%. In multivariate analysis, age (<40) and low bone marrow blast were associated with better EFS, while no difference was observed between the two centers. The patients enrolled in study were unselected, representing typical patients' population of refractory AML, and primary data demonstrated the feasibility of sequential conditioning regimen.
format Online
Article
Text
id pubmed-6462832
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-64628322019-09-27 Clinical outcome of FLAG-IDA chemotherapy sequential with Flu–Bu3 conditioning regimen in patients with refractory AML: a parallel study from Shanghai Institute of Hematology and Institut Paoli-Calmettes Wang, Ling Devillier, Raynier Wan, Ming Decroocq, Justine Tian, Liang Fürst, Sabine Wang, Li-Ning Vey, Norbert Fan, Xing Blaise, Didier Hu, Jiong Bone Marrow Transplant Article The purpose of the study was to evaluate the feasibility of conditioning regimen with sequential chemotherapy (FLAG-IDA), followed by Fludarabine (5 days) + Busulfan (3 days) by parallel analysis of patients with refractory acute myeloid leukemia (AML) from two transplantation centers in China and France. A total of 47 refractory AML with median bone marrow blast of 35% (1–90%) and median age at 42 years (16–62) were enrolled. Thirteen patients received peripheral stem cell transplantation (HSCT) from HLA-matched sibling donor, while 18 and 16 from unrelated or haplo-identical donors, respectively. With a median follow-up of 24.3 months (1–70), 13 patients relapsed at a median time of 5.1 months (2.2–18.0) and 24 patients died due to relapse (n = 12) or non-relapsed mortality (NRM, n = 12). The estimated 3-year RR and NRM were 33.5 ± 5.7% and 25.7 ± 4.2%, respectively. The estimated 3-year overall survival (OS) and event-free survival (EFS) were 43.8 ± 7.8% and 42.3 ± 7.8%. In multivariate analysis, age (<40) and low bone marrow blast were associated with better EFS, while no difference was observed between the two centers. The patients enrolled in study were unselected, representing typical patients' population of refractory AML, and primary data demonstrated the feasibility of sequential conditioning regimen. Nature Publishing Group UK 2018-08-06 2019 /pmc/articles/PMC6462832/ /pubmed/30082853 http://dx.doi.org/10.1038/s41409-018-0283-5 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Wang, Ling
Devillier, Raynier
Wan, Ming
Decroocq, Justine
Tian, Liang
Fürst, Sabine
Wang, Li-Ning
Vey, Norbert
Fan, Xing
Blaise, Didier
Hu, Jiong
Clinical outcome of FLAG-IDA chemotherapy sequential with Flu–Bu3 conditioning regimen in patients with refractory AML: a parallel study from Shanghai Institute of Hematology and Institut Paoli-Calmettes
title Clinical outcome of FLAG-IDA chemotherapy sequential with Flu–Bu3 conditioning regimen in patients with refractory AML: a parallel study from Shanghai Institute of Hematology and Institut Paoli-Calmettes
title_full Clinical outcome of FLAG-IDA chemotherapy sequential with Flu–Bu3 conditioning regimen in patients with refractory AML: a parallel study from Shanghai Institute of Hematology and Institut Paoli-Calmettes
title_fullStr Clinical outcome of FLAG-IDA chemotherapy sequential with Flu–Bu3 conditioning regimen in patients with refractory AML: a parallel study from Shanghai Institute of Hematology and Institut Paoli-Calmettes
title_full_unstemmed Clinical outcome of FLAG-IDA chemotherapy sequential with Flu–Bu3 conditioning regimen in patients with refractory AML: a parallel study from Shanghai Institute of Hematology and Institut Paoli-Calmettes
title_short Clinical outcome of FLAG-IDA chemotherapy sequential with Flu–Bu3 conditioning regimen in patients with refractory AML: a parallel study from Shanghai Institute of Hematology and Institut Paoli-Calmettes
title_sort clinical outcome of flag-ida chemotherapy sequential with flu–bu3 conditioning regimen in patients with refractory aml: a parallel study from shanghai institute of hematology and institut paoli-calmettes
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6462832/
https://www.ncbi.nlm.nih.gov/pubmed/30082853
http://dx.doi.org/10.1038/s41409-018-0283-5
work_keys_str_mv AT wangling clinicaloutcomeofflagidachemotherapysequentialwithflubu3conditioningregimeninpatientswithrefractoryamlaparallelstudyfromshanghaiinstituteofhematologyandinstitutpaolicalmettes
AT devillierraynier clinicaloutcomeofflagidachemotherapysequentialwithflubu3conditioningregimeninpatientswithrefractoryamlaparallelstudyfromshanghaiinstituteofhematologyandinstitutpaolicalmettes
AT wanming clinicaloutcomeofflagidachemotherapysequentialwithflubu3conditioningregimeninpatientswithrefractoryamlaparallelstudyfromshanghaiinstituteofhematologyandinstitutpaolicalmettes
AT decroocqjustine clinicaloutcomeofflagidachemotherapysequentialwithflubu3conditioningregimeninpatientswithrefractoryamlaparallelstudyfromshanghaiinstituteofhematologyandinstitutpaolicalmettes
AT tianliang clinicaloutcomeofflagidachemotherapysequentialwithflubu3conditioningregimeninpatientswithrefractoryamlaparallelstudyfromshanghaiinstituteofhematologyandinstitutpaolicalmettes
AT furstsabine clinicaloutcomeofflagidachemotherapysequentialwithflubu3conditioningregimeninpatientswithrefractoryamlaparallelstudyfromshanghaiinstituteofhematologyandinstitutpaolicalmettes
AT wanglining clinicaloutcomeofflagidachemotherapysequentialwithflubu3conditioningregimeninpatientswithrefractoryamlaparallelstudyfromshanghaiinstituteofhematologyandinstitutpaolicalmettes
AT veynorbert clinicaloutcomeofflagidachemotherapysequentialwithflubu3conditioningregimeninpatientswithrefractoryamlaparallelstudyfromshanghaiinstituteofhematologyandinstitutpaolicalmettes
AT fanxing clinicaloutcomeofflagidachemotherapysequentialwithflubu3conditioningregimeninpatientswithrefractoryamlaparallelstudyfromshanghaiinstituteofhematologyandinstitutpaolicalmettes
AT blaisedidier clinicaloutcomeofflagidachemotherapysequentialwithflubu3conditioningregimeninpatientswithrefractoryamlaparallelstudyfromshanghaiinstituteofhematologyandinstitutpaolicalmettes
AT hujiong clinicaloutcomeofflagidachemotherapysequentialwithflubu3conditioningregimeninpatientswithrefractoryamlaparallelstudyfromshanghaiinstituteofhematologyandinstitutpaolicalmettes